
Article 1 
Annexes I and II of Decision 2008/911/EC are amended in accordance with the Annex to this Decision.
Article 2 
This Decision is addressed to the Member States.
Done at Brussels, 28 November 2011.
For the Commission
John DALLI
Member of the Commission
ANNEX

Annexes I and II to Decision 2008/911/EC are amended as follows:

1.. in Annex I, the following substance is inserted after Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung (sweet fennel fruit):
'Hamamelis virginiana L., folium et cortex aut ramunculus destillatum';
2.. in Annex II, the following is inserted after the entry relating to Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung, fructus:
'
Hamamelis virginiana L.

Hamamelidaceae


1.. Distillate prepared from fresh leaves and bark (1:1.12 – 2.08; extraction solvent ethanol 6 % m/m)
2.. Distillate prepared from dried twigs (1:2; extraction solvent ethanol 14-15 %)

Not applicable

Traditional herbal medicinal product for relief of minor skin inflammation and dryness of the skin.

Traditional herbal medicinal product to be used for the temporary relief of eye discomfort due to dryness of the eye or to exposure to wind or sun.

The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

European

Please see ‘Specified posology’.

Distillate in a strength corresponding to 5-30 % in semi-solid preparations, several times daily.

The use in children under six years of age is not recommended (see section ‘Special warnings and precautions for use’).

Eye drops Distillate (2) diluted (1:10), 2 drops/each eye, 3-6 times daily.

The use in children under 12 years of age is not recommended (see section ‘Special warnings and precautions for use’).


 Cutaneous use.
 Ocular use.

If the symptoms persist longer than two weeks during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.

The recommended duration of use is four days. If the symptoms persist longer than two days during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.

Hypersensitivity to the active substance.

The use in children under six years of age has not been established due to lack of adequate data.

If eye pain, changes in vision, continued redness, or irritation of the eye is experienced, or if the condition worsens or persists for more than 48 hours during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.

The use in children under 12 years of age has not been established due to lack of adequate data.

For extracts containing ethanol, the appropriate labelling for ethanol, taken from the ‘Guideline on excipients in the label and package leaflet of medicinal products for human use’, must be included.

None reported.

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

No studies on the effect on the ability to drive and use machines have been performed.

Allergic contact dermatitis may occur in sensitive patients. The frequency is not known.

Conjunctivitis cases have been reported. The frequency is not known.

If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted.

No case of overdose has been reported.

Not applicable.

Not applicable.
'.
